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Abstract
Background: We investigated associations between signal transducer and activator of transcription (STAT) 1 in pretreated
liver tissues, interleukin (IL) 28B polymorphism and treatment response in hepatitis C virus (HCV)-infected patients treated
with peginterferon and ribavirin.
Methods and Findings: We performed immunostaining analysis of STAT1 in liver tissues and determined IL28B
polymorphism at rs8099917. We then compared the results with treatment outcomes in HCV genotype 1 patients with high
viral load who were receiving peginterferon plus ribavirin. In univariate analysis, younger age, white blood cell counts,
virological responder, early virological responder (EVR), mild activity (A1) of liver inflammation grading, and lower STAT1
nuclear-stain of hepatocytes in zone 1, zone 2 and total zones of liver were associated with sustained virological responder
(SVR). Multivariate analysis showed that EVR, age and hepatic STAT1 nuclear-stain in zone 2 of liver were independent
predictors of SVR. It was also revealed that IL28B and STAT1-nuclear translocation in hepatocytes are independent
predictors of response to treatment with peginterferon and ribavirin in chronic hepatitis C patients.
Conclusions: Concomitant assessment of lower STAT1 nuclear-stain of hepatocytes and IL28B polymorphism is useful for
prediction of SVR in HCV genotype 1 patients.
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Introduction
Hepatitis C virus (HCV) chronically infects ,170 million people
worldwide and ,3.1 million people in the US [1,2]. Chronic
HCV infection can cause chronic liver disease, cirrhosis and
hepatocellular carcinoma (HCC) [3]. Treatment with peginter-
feron alfa and ribavirin leads to a sustained virological response
(SVR) in ,50% of patients infected with HCV genotype 1 with 48
weeks of therapy and ,80% of patients infected with HCV
genotype 2 or 3 with a 24-week course [4–6].
It has recently been reported that single nucleotide polymor-
phisms (SNPs) in the 19q13 region, in close proximity to three
genes (IL28A, IL28B and IL29) encoding cytokines of the
interferon lambda (i.e. type III interferon) family are strongly
associated with the treatment response to peginterferon alfa and
ribavirin among HCV genotype 1-infected individuals [7–10].
One of these SNPs, rs8099917, is reportedly highly predictive of a
favorable treatment response among patients infected with
Japanese HCV genotype 1. Null responsiveness to interferon was
used in the analysis that endorsed rs8099917 [8].
Interferon lambda utilizes a receptor complex different from
interferon alfa, but both types of interferon induce signal transducer
and activator of transcription 1 (STAT1) and STAT2, as well as
STAT3 activation [11]. Activation of the interferon receptor leads to
atleast onecytoplasmJanustyrosine proteinkinase (Jak1).Interferon
stimulation results in tyrosine phosphorylation, dimerization, and
nuclearimportofSTATs [12].STATs andtheinterferon-stimulated
gene factor 3 (ISGF3) transcription factor complex moves into the
nucleus, binds to interferon-stimulated response elements (ISRE) in
the promoters of the interferon-stimulated genes (ISGs) like 29,5 9-
oligoadenylate synthetase (OAS) and Myxovirus resistance protein A
(MxA) genes, and induces transcription of those genes. Gene
expression array analysis showed that interferons alfa and lambda
induced a similar subset of genes although interferon lambda
signaling was observed for more restricted cell lines. Interferon
lambda has been shown to be induced after stimulation with several
single-stranded RNA (ssRNA) viruses [13]. There was a report that
the antiviral activity of type III interferon surpassed that of type I
interferon [14]. There are several reports concerning HCV
interfering with the Jak/STAT signaling pathway [15,16].
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of ISGs before therapy [17]. Sarasin-Filipowicz et al. [18] reported
that phospholyration, DNA binding, and nuclear localization of
STAT1 were pre-activated and refractory to further stimulation in
nonresponsive patients. Several recent studies suggested that the
expressions of ISGs in liver [19] and plasma [20] are associated
with genetic variation in IL28B and the outcome of interferon
therapy for chronic hepatitis C. The expression of hepatic ISGs is
strongly associated with treatment response and genetic variation
of IL28B [19]. The favorable IL28B SNP variants are also
associated with lower baseline interferon-gamma-inducible protein
10 kDa (IP-10 or CXCL10) [20].
The impact of STAT1 on the elimination of HCV RNA during
therapy in the setting of IL28B genetic variants is unknown. We
therefore assessed the nuclear translocation of STAT1 in pre-
treatment liver biopsies and IL28B rs8099917 in patients
chronically infected with HCV genotype 1. We also correlated
the biochemical data with the treatment response, and all resulting
data were analyzed.
Materials and Methods
Patients
Between February 2010 and June 2011, 202 patients with
chronic hepatitis C were recruited into the present study at the
Department of Gastroenterology, Chiba University Medical
School Hospital, Chiba, Japan. Some of these patients had
already been included in previous reports [10]. The baseline
characteristics are listed in Table 1.
All patients were adults, had compensated liver disease, and
fulfilled the inclusion criterion of a positive test for anti-HCV
antibody and HCV RNA. All these patients had samples available
for IL28B analysis, and 79 of them underwent liver biopsy for
samples for evaluation of hepatic STAT1. This study was
approved by the ethics committee of Chiba University, Japan
(permission number 247 and 840), and conformed to the Helsinki
Declaration. Written informed consent was obtained from all
patients before enrollment in this study. This work was partly
presented at the HCV2011 18
th International Symposium on
Hepatitis C Virus and Related Viruses on September 9, 2011,
Seattle, WA, USA.
Treatment
One hundred twenty-four patients were treated with pegylated
interferon alfa once weekly and 400–1,000 mg of ribavirin orally
twice daily [10]. Some of the patients stopped treatment at 12–16
weeks according to the early stopping rule. Fifteen, 78, and 28
received treatment for ,48, 48 and 72 weeks, respectively. The
duration of treatment was unknown in 3 patients. Seventy-nine of
these 124 HCV patients, evaluated for hepatic STAT1, received
treatment for 48 weeks or longer.
HCV Genotyping
HCV genotype was determined using the antibody serotyping
assay of Tsukiyama-Kohara et al. [21]. In this assay, HCV
serotypes 1 and 2 correspond to genotypes 1a/1b and 2a/2b,
respectively, according to the classification of Simmonds et al.
[22]. It was reported that in 84% patients, genotypes determined
by this serological genotyping assay showed complete agreement
with those determined by group-specific PCR, with none revealing
a group opposite to that of the HCV genotype, and also that the
detection rate of this assay was even higher than that of the PCR
assay.
HCV RNA Quantification
HCV RNA was determined by an Amplicor HCV monitor
assay, version 2.0 (range: 0.5–850 KIU/mL) (Roche Diagnostics,
Tokyo, Japan), Amplicor HCV assay (Roche) or COBAS TaqMan
HCV test (Roche) (range: 1.2–7.8 log IU/mL). The detection limit
of this qualitative assay is 50 IU/mL, corresponding to 1.7 log IU/
mL by COBAS TaqMan PCR assay [23]. We defined HCV
RNA$5 log IU/mL and ,5 log IU/mL as high and low viral titer
of HCV RNA, respectively.
Classification of Treatment Outcome
Patients were classified as having achieved RVR and EVR if
HCV RNA was undetectable (,50 IU/mL) in serum at treatment
week 4 and week 12, respectively, and as having SVR if HCV
RNA was undetectable in serum 24 weeks after the completion of
therapy.
Liver Biopsies
Liver biopsies were obtained from 79 patients, and the samples
were processed for both histological evaluation (hematoxylin and
eosin) and staining for STAT1.
STAT1 Immunohistochemistry
Liver sections were cut from paraffin blocks and captured on
electricallychargedslides.Sectionsweredewaxedinxyleneandtaken
through a series of ethanol washes. Antigen retrieval was performed
by autoclave pressure for 10 minutes at full pressure in 10 mmol/L
sodium citrate buffer (pH 7.0) (Mitsubishi Chemical Medience,
Tokyo, Japan). Endogenous peroxidase activity was blocked by
incubation in 3% hydrogen peroxide for 30 minutes. Anti-Stat1
rabbit monoclonal antibody (42H3, Cell Signaling Technology,
Boston, MA) was incubated at a dilution of 1:200 overnight at 4uC,
and immunodetection was done with an ImmPRESS anti-rabbit Ig
reagent kit (Vector Laboratories, Burlingame, CA). Sections were
counterstained with Meyer’s hematoxylin solution (Wako Pure
Table 1. Basic characteristics of patients infected with HCV.
IL28B rs8099917 Total Major Minor P-value
No. of patients 202 134 68
Age, y 55.4611.7 56.6611.1 53.1612.4 0.0431
Gender (M/F) 101/101 64/70 37/31 NS
HCV RNA (H/L/U) 191/10/1 125/9/0 66/1/1 NS
Genotype (G1/G2/U) 166/34/2 111/22/1 55/12/1 NS
ASL (IU/L) 57.2643.9 56.4647.9 58.7634.9 NS
ALT (IU/L) 69.9660.0 67.5663.3 74.7653.2 NS
G-GTP (IU/L) 52.5660.6 42.5638.3 72.0686.6 0.000949
WBC (/mm
3)5 , 2 4 0 61,520 5,27061,620 5,17061,320 NS
Hb (g/dL) 14.061.3 14.061.2 14.161.3 NS
Platelets (610
4/mm
3) 17.365.8 17.565.7 17.166.0 NS
DM (+/2/U) 30/169/3 18/114/2 12/55/1 NS
US (CH/LC/U) 163/33/6 112/19/3 51/14/3 NS
We defined IL28B rs8099917 TT (n=134) as major type and TG (n=64) and GG
(n=4) as minor type.
H, high viral load (65 log IU/mL); L, low viral load (,5 log IU/mL); G1, genotype
1; G2, genotype 2; U, unknown; WBC, white blood cell count; Hb, hemoglobin;
DM, diabetes mellitus; US, ultrasound finding; CH, chronic hepatitis; LC, liver
cirrhosis; NS, not significant.
doi:10.1371/journal.pone.0028617.t001
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according to Rappaport’s classification [24] as follows: zone 1, acini
centered on the portal triad; zone 3, the circulatory peripheries of
acini (adjacent to terminal hepatic vein); zone 2, acini between zone 1
and zone 3. We counted 200 cells in each zone, and then recorded
the percentage of cells with positive STAT1-nuclear translocation per
total cell numbers.
DNA extraction
Human genomic DNA was extracted from 1 mL of blood
samples using a QIAamp DNA Blood Midi Kit (QIAGEN, Tokyo,
Japan) and quantitated on UV visible spectrophotometer Ultros-
pec 3,000 (Pharmacia Biotech, Piscataway, NJ).
IL28B genotyping
DNA samples from patients and controls were genotyped for
the IL28B rs8099917 polymorphism with a simple assay based on
restriction fragment length polymorphism methods [10] or
TaqMan SNP genotyping assay (Applied Biosystems Inc, Foster
City, CA) using the ABI Step One real-time PCR system,
according to the manufacturer’s recommended protocols. Taq-
Man probes and primers were designed and synthesized by
Applied Biosystems. We analyzed IL28B rs8099917 TT as major
type and TG and GG as minor type in the present study.
Statistical analysis
Data were expressed as mean 6 standard deviation (SD).
Differences were evaluated by Student t-test, Chi-square test, or
Fisher’s exact test. P,0.05 was considered statistically significant.
Variables with P,0.05 at univariate analysis were retained for
multivariate logistic-regression analysis. For all tests, two-sided P-
values were calculated and the results were considered statistically
significant at P,0.05. Statistical analysis was performed using the
Excelstatistics program for Windows, version 7 (SSRI, Tokyo,
Japan) and DA Stats software (O. Nagata, Nifty Serve: PAF01644).
Results
IL28B rs8099917 in Japanese patients infected with HCV
Characteristics of the 202 patients in the present study are
summarized in Table 1. IL28B rs8099917 TT, TG and GG were
134, 64 and 4 patients, respectively. Patients with IL28B rs8099917
major type were significantly older than those with IL28B rs8099917
m i n o rt y p e( T a b l e1 ) .T h e r ew e r en od i f f e r e n c e si ng e n d e r
distribution, HCV RNA levels, HCV genotype, ALT, AST, white
blood cell counts, hemoglobin, platelet counts, complication with Table 2. No correlation between STAT1-nuclear translocation
and IL28B genotypes.
IL28B rs8099917 Total Major Minor P-value
No. of patients 79 53 26
Age, y 54.4611.6 55.8610.4 51.5613.5 NS
Gender (M/F) 37/42 24/29 13/13 NS
ASL (IU/L) 58.0651.5 60.0659.6 54.0629.2 NS
ALT (IU/L) 69.2661.7 71.1670.4 65.4639.5 NS
G-GTP (IU/L) 40.8625.4 35.6624.0 51.4625.3 0.00849
WBC (/mm
3)5 , 1 9 0 61,320 5,33061,420 4,90061,070 NS
Hb (g/dL) 14.461.2 14.361.2 14.561.2 NS
Platelets (610
4/mm
3) 17.066.5 17.366.1 16.567.3 NS
DM (+/2/U) 12/67/0 6/47/0 6/20/0 NS
US (CH/LC/U) 63/15/1 42/11/0 21/4/1 NS
VR/Null Responder 51/28 39/14 12/14 0.0319
RVR (+/2) 2/77 1/52 1/25 NS
EVR (+/2) 28/51 24/29 4/22 0.0182
SVR (+/2) 29/50 24/29 5/21 0.0445
Liver Biopsy
F (F1/F2/F3/F4) 29/25/15/10 20/16/10/7 9/9/5/3 NS
A (A1/A2/A3) 28/43/8 20/29/4 8/14/4 NS
Nuclear-STAT1 (%)
Zone 1 9.1468.11 8.6567.67 10.169.03 NS
Zone 2 3.7863.94 3.7464.20 3.8663.43 NS
Zone 3 7.4167.07 6.9066.76 8.4467.71 NS
Total 6.5765.29 6.2865.58 7.1664.69 NS
We defined IL28B rs8099917 TT (n=134) as major type and TG (n=64) and GG
(n=4) as minor type.
U, unknown; WBC, white blood cell count; Hb, hemoglobin; DM, diabetes
mellitus; US, ultrasound findings; CH, chronic hepatitis; LC, liver cirrhosis; VR,
virological responder; RVR, rapid virological responder; EVR, early virological
responder; SVR, sustained virological responder; F, Staging of Fibrosis; A,
Grading of Activity; nuclear-STAT1, STAT1-nuclear translocation; NS, not
significant.
doi:10.1371/journal.pone.0028617.t002
Table 3. Correlation between STAT1-nuclear translocation
and SVR.
Treatment response Total SVR Non-SVR P-value
No. of patients 79 29 50
Age, y 54.4611.6 49.0613.6 57.569.0 0.00128
Gender (M/F) 37/42 18/11 19/31 0.0668
ASL (IU/L) 58.0651.5 59.3677.7 57.3627.9 NS
ALT (IU/L) 69.2661.7 79.5690.3 63.3636.2 NS
G-GTP (IU/L) 40.8625.4 36.3630.0 43.4622.3 NS
WBC (/mm
3) 5,19061,320 5,61061,410 4,94061,220 0.0292
Hb (g/dL) 14.461.2 14.661.2 14.261.2 NS
Platelets (610
4/mm
3) 17.066.5 18.965.1 15.967.0 0.0472
DM (+/2) 12/67 3/26 9/41 NS
VR/Null Responder 51/28 29/0 22/28 0.00000182
RVR (+/2) 2/77 2/27 0/50 NS
EVR (+/2) 28/51 21/8 7/43 0.000000610
Liver Biopsy
F (F1/F2/F3/F4) 29/25/15/10 13/11/4/1 13/11/4/1 NS
F (F1+F2/F3+F4) 54/25 24/5 30/20 0.0649
A (A1/A2/A3) 28/43/8 15/13/1 13/30/7 NS
A (A1/A2+A3) 28/51 15/14 13/37 0.0394
Nuclear-STAT1 (%)
Zone 1 9.1468.11 6.4965.68 10.668.93 0.0288
Zone 2 3.7863.94 2.5163.31 4.5264.12 0.0280
Zone 3 7.4167.07 5.6666.42 8.4267.30 0.0948
Total 6.5765.29 4.7764.51 7.6165.46 0.0203
WBC, white blood cell count; Hb, hemoglobin; DM, diabetes mellitus; US,
ultrasound finding; CH, chronic hepatitis; LC, liver cirrhosis; VR, virological
responder; RVR, rapid virological responder; EVR, early virological responder;
SVR, sustained virological responder; F, Staging of Fibrosis; A, Grading of
Activity; nuclear-STAT1, STAT1-nuclear translocation; NS, not significant.
doi:10.1371/journal.pone.0028617.t003
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but we noticed that gamma-GTP levels of IL28B rs8099917 minor
typewerehigherthanthoseofIL28Brs8099917majortype(Table1).
IL28B rs8099917 and treatment response
Among the total patients, we analyzed 79 HCV genotype 1-
infected patients who were treated with peginterferon plus
ribavirin and underwent liver biopsies (Table 2). IL28B
rs8099917 TT, TG and GG were 53, 25 and 1 patients,
respectively. This distribution was similar to that of the total 202
HCV-infected Japanese patients (statistically not significant).
The proportions of virological responders (VRs) and early
virological responders (EVRs) in the 53 patients with IL28B
rs8099917 major type were higher than those in the 26 patients
with IL28B rs8099917 minor type (Table 2). It was also confirmed
that gamma-GTP levels of IL28B rs8099917 minor type were
higher than those of IL28B rs8099917 major type in this
population (Table 2).
IL28B rs8099917, STAT1-nuclear translocation in
hepatocytes and liver histology
In the present study, histological analysis of the pre-treatment
liver samples revealed that there was no association between
IL28B genotypes and staging of fibrosis nor association between
IL28B genotypes and grading of inflammatory activity of the liver
(Table 2).
Liver fibrosis was not correlated with STAT1-nuclear translo-
cation in hepatocytes, but the activity of liver inflammation was
correlated with STAT1-nuclear translocation in hepatocytes [mild
activity (A1) vs. moderate activity (A2) and severe activity (A3):
P=0.0016 in zone 1; P=0.00026 in zone 2; P=0.0022 in zone 3;
P=0.00018 in all zones; data not shown]. Further, there was no
association between STAT1-nuclear translocation in hepatocytes
and IL28B rs8099917 (Table 2).
Predictors of SVR
Table 3 shows the pre-treatment and treatment factors of HCV
genotype 1-infected patients between the achieving and not
achieving SVR groups. Univariate analysis showed that age, white
blood cell counts, platelet counts, achieving virological response,
achieving early virological response, and STAT1-nuclear translo-
cation in zone 1, in zone 2, and in total number contributed to the
achievement of SVR (Table 3). Factors significantly associated
with SVR by univariate analysis were then subjected to
multivariate logistic regression analysis. In HCV genotype 1-
infected patients with higher viral load, EVR, age and STAT1-
nuclear localization in zone 2 were independent predictors of SVR
(P,0.0001, P=0.011 and P=0.032, respectively).
In the present study, only 2 of 79 HCV genotype 1-infected
patients with high viral load achieved RVR, and these 2 patients
also achieved SVR. Typical immune-histochemical analysis for
STAT1 in hepatocytes is shown in Figure 1.
Performance of IL28B rs8099917 and STAT1-nuclear
translocation for predicting SVR
IL28B major genotype, which has been associated with better
treatment response in several previous studies, was identified in 53
patients, and 24 of them (45.2%) achieved SVR (Tables 2 and 4).
In the other 26 patients with IL28B minor genotype, 5 (19.2%)
achieved SVR. STAT1-nuclear translocation in hepatocytes
augmented the prediction of SVR among genotype 1-infected
patients for IL28B major genotype (Table 4).
Discussion
In the present study, we confirmed that IL28B rs8099917 is
useful for predicting null responders as was shown in previous
studies. We also observed that STAT1, one of the ISGs, showed
greater activation in pre-treatment hepatocytes of patients without
SVR. Furthermore, the combination of STAT1-nuclear translo-
Figure 1. Immunohistochemistry for STAT1 in pretreated liver biopsy samples. (A)–(C) Patients with achievement of SVR. (D)–(F) Patients
without achievement of SVR. (A) From a patient infected with HCV G1, high viral load (SVR, IL28B rs8099917TT). Arrowheads show markedly reduced
nuclear staining for STAT1. (B) From a patient infected with HCV G1, high viral load (SVR, IL28B rs8099917TT). Arrowheads show markedly reduced
nuclear staining for STAT1. (C) From a patient infected with HCV G1, high viral load (SVR, IL28B rs8099917TG). Arrow, bile duct; arrowheads show
markedly reduced nuclear staining for STAT1. (D) From a patient infected with HCV G1, high viral load (Null responder, IL28B rs8099917TG).
Arrowheads show more distinct nuclear staining for STAT1. (E) From a patient infected with HCV G1, high viral load (Relapser, IL28B rs8099917TT).
Arrowheads show more distinct nuclear staining for STAT1. (F) From a patient infected with HCV G1, high viral load (Relapser, IL28B rs8099917TT).
Arrow, bile duct; Arrowheads show more distinct nuclear staining for STAT1.
doi:10.1371/journal.pone.0028617.g001
STAT1 and IL28B in Chronic Hepatitis C
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useful for the prediction of SVR in HCV genotype 1-infected
patients with high viral load when they receive the combination
peginterferon plus ribavirin therapy.
We observed the differences of STAT1-nuclear translocation in
hepatocytes between SVR- and non-SVR-patients in zones 1 and
2, but not in zone 3. In chronic persistent hepatitis, weak
membranous staining of human interferon gamma receptors was
found on a number of scattered hepatocytes in acinar zone 1, with
more pronounced expression on single hepatocytes in acinar zone
3 [25]. Honda et al. [26] reported that different interferon
signaling in the liver lobule area (zone 2) and portal area (zone 1)
under treatment for chronic hepatitis C. These data indicate that
analysis of hepatocytes in each zone might be useful for the
prediction of SVR in antiviral treatment of chronic hepatitis C
patients.
In the case of West Nile virus (WNV) infection, only interferon
lambda-induced activation of Jak-STAT signaling pathway and
induction of ISG expression were completely inhibited in WNV
replicon-containing cell lines, but interferon alfa signal transduc-
tion was either unaffected or only partially inhibited in Huh7.5 or
Hela cells by the virus [27]. The differential inhibition of WNV by
interferon alfa and interferon lambda signal transduction implies
that there could be differences between the two types of interferon-
receptors or -signalings. Further studies are also needed in HCV
infection.
Rapid virological response (RVR) is well known to be an
important predictor of SVR in combination therapy [6,28].
However, RVR is less observed in HCV genotype 1-patients with
high viral load. This means that other predictors are needed.
IL28B variants were found not to be linked to STAT1-nuclear
translocation (Table 2), although our present study had a rather
small sample size. Our finding that STAT1-nuclear translocation
was activated less in pre-treatment hepatocytes of patients with
SVR than in those without SVR is in line with recent reports
[19,20]. There have been several reports that activation of ISGs at
baseline levels of the liver among IL28B unfavorable carriers is
typically observed in patients who respond less favorably to
treatment [19,29–31], although Dill et al. [32] reported that
IL28B genotype and hepatic expression of ISG are independent
predictors of response to treatment in chronic hepatitis C patients.
Urban et al. [29] reported the fact that IL28B genotype may
explain the relationship between hepatic ISG expression and HCV
treatment outcome is independent of miR-122 expression. The
present study is the first report concerning IL28B and STAT1-
nuclear translocation in hepatocytes being independent predictors
of response to treatment with peginterferon and ribavirin in
chronic hepatitis C patients.
In conclusion, we found that IL28B and hepatic STAT1-
nuclear translocation are independent predictors of treatment
response. Concomitant assessment of pre-treatment STAT1-
nuclear translocation in hepatocytes and IL28B rs8099917
favorable genotype improves the prediction of SVR in HCV
genotype 1-infected patients with high viral load in the treatment
of peginterferon plus ribavirin therapy.
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